Clinical trials: Intermediate Risk Prostate Cancer, open to volunteers
Prostate Cancer, Localized Prostate Carcinoma
Erectile Function PRESERVation in Definitive Radiotherapy for Prostate Cancer by MRI-Enhanced Adaptive Sparing of the Neurovascular Bundle
Radiotherapy is a standard and highly effective treatment for prostate cancer that is confined to the prostate gland. One modern approach, called stereotactic body radiotherapy (SBRT), delivers treatment in just five sessions and…
- Conditions
- Prostate Cancer, Localized Prostate Carcinoma, Low-Risk Prostate Cancer, Intermediate-risk Prostate Cancer
- Trial name
- EF-PRESERVE (NCT07916779)
- Testing
- Daily Adaptive MR-Enhanced SBRT with Neurovascular Bundle Sparing
- Where
- Switzerland
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Prostate Cancer Patients, Non-metastatic Prostate Cancer
Radiation Therapy Approaches for People With Prostate Cancer
The purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.
- Conditions
- Prostate Cancer Patients, Non-metastatic Prostate Cancer, High Risk Prostate Cancer
- Trial name
- NCT07751159
- Testing
- Standard of Care HDR Brachytherapy, SBRT
- Where
- 7 sites in United States
- Volunteers
- 126 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
A Pan-Canadian, Investigator Initiated Clinical Trial With Focal IRE Directed to Intermediate-Risk Prostate Cancer
The goal of this clinical trial is to investigate the safety and efficacy of Irreversible Electroporation (IRE) using NanoKnife technology in patients with intermediate-risk prostate cancer.
- Trial name
- WIRED (NCT06451445)
- Testing
- Irreversible Electroporation (NanoKnife)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment.
- Conditions
- Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
- Trial name
- ARPEGGIO (NCT07393867)
- Testing
- PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Martin T. King, MD, PhD
Prostate Cancer (Adenocarcinoma)
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.
Patients with unfavorable intermediate-risk prostate cancer will be randomized between 6 versus 12 months of hormone therapy with radiation therapy.
- Trial name
- PCS-XII (NCT06855589)
- Testing
- 6 months of Eligard, 12 months of Eligard, prostate SBRT or prostate brachytherapy with radiation therapy
- Where
- 5 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Charles LeMoyne Hospital
Low-to-intermediate-risk Prostate Carcinoma
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)
A single institution with a single group, a phase II study, low- and medium-risk studies performed after biodegradable substance injection prostate cancer dosage increase.
- Trial name
- DESAR-L (NCT06461819)
- Testing
- Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Prostate Carcinoma, Stage I Prostate Cancer AJCC v8
MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer
This clinical trial tests whether the magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) procedure is safe and effective in treating patients with low to intermediate grade prostate cancer.
- Conditions
- Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT05438563
- Testing
- MRI-Guided Transurethral Ultrasound Ablation, Questionnaire Administration, Digital Rectal Examination
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Prostate CA
Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer
Prostate cancer is a common cancer, and a significant cause of cancer death in men. There are many potentially curative treatment options for prostate cancers that have not spread.
- Trial name
- ADAPT-25 (NCT06835725)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
- Trial name
- PSMA SBRT-SIB (NCT04402151)
- Testing
- PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized…
- Trial name
- NCT01492972
- Testing
- Radiation, Androgen Suppression Therapy
- Where
- 4 sites in United States
- Volunteers
- 192 people
- Sponsor
- Proton Collaborative Group
Localized Prostate Cancer
Focal Micro-boost Strategy in Patients With Intermediate- to High-risk Prostate Cancer (IR-HR PCa) Undergoing Hypofractionated Radiotherapy
HYPO62 SPECIAL is a monocentric, prospective observational cohort study promoted by IFO-IRE/ISG, designed to evaluate a moderately hypofractionated radiotherapy strategy with focal micro-boost in patients with localized…
- Trial name
- 62SPECIAL (NCT07792993)
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Regina Elena Cancer Institute
Prostate Cancer
MICRO-ultrasound Guided Prostate SBRT
This study will test whether it is safe and effective to use stereotactic body radiation therapy (SBRT)-a short, targeted form of radiation-together with a microultrasound (microUS)-guided radiation boost to the cancerous spots…
- Trial name
- MICRO-S (NCT07737457)
- Testing
- Stereotactic Body Radiation Therapy, ExactVu
- Where
- Canada
- Volunteers
- 112 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Prostate Cancer
A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer
The primary objective of this study is to evaluate the safety and effectiveness of PFA in patients with localized prostate cancer.
- Trial name
- NCT07492381
- Testing
- ALPFA BPH PFA System
- Volunteers
- 50 people
- Sponsor
- ALPFA Medical
Prostate Cancer
Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer
On the basis of the now consolidated literature and clinical experience of focal therapies, the execution of partial prostatectomy/hemiprostatectomy with robot-assisted laparoscopic technique can be proposed in a well-selected…
- Trial name
- RETURN (NCT05832736)
- Testing
- Robotic hemi-prostatectomy with urethral preservation
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Prostate Cancer Patients Treated by Radiotherapy
Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial
This study is testing a shorter treatment method for prostate cancer using proton therapy (PT), which is very precise and may cause fewer side effects compared to traditional radiation.
- Trial name
- PT2 (NCT07130682)
- Testing
- Pencil Beam Proton Therapy Treatment Machine
- Where
- Hong Kong
- Volunteers
- 35 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Prostate Cancer
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to…
- Trial name
- HypoPro (NCT06772441)
- Testing
- Androgen deprivation therapy (ADT)
- Where
- Cyprus
- Volunteers
- 30 people
- Sponsor
- German Oncology Center, Cyprus
PROSTATE CANCER
Two-fraction Versus Five-fraction Stereotactic Radiotherapy for Localized Prostate Cancer
The goal of this clinical trial is to compare two dose schedules of stereotactic radiation therapy in patients with localized prostate cancer.
- Trial name
- SABR-Dual (NCT06027892)
- Testing
- Two-fraction stereotactic radiotherapy, Five-fraction stereotactic radiotherapy
- Where
- Israel
- Volunteers
- 562 people
- Sponsor
- Rabin Medical Center
Prostate Cancer
Two Fraction Prostate SBRT With DIL SIB
Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic classification in the…
- Trial name
- NCT05864196
- Testing
- Two-Fraction Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- NYU Langone Health
Prostate Cancer
An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
To learn if using cryotherapy to treat only the part of the prostate known to contain cancer is effective in controlling prostate cancer
- Trial name
- NCT05454488
- Testing
- Focal Cryoablation, Standard of Care, Quality-of-life Questionnaires
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Single-Dose Image-Guided Radiotherapy With Urethral Sparing and DIL Boost for Intermediate-Risk Prostate Cancer (PROSINT II)
This prospective single-arm phase II study evaluates the safety, feasibility, quality-of-life effects, PSA kinetics, imaging response, and clinical outcomes of definitive ultra-high dose single-fraction external beam radiation…
- Trial name
- PROSINT II (NCT04035642)
- Testing
- IGRT-VMAT / SDRT 24 Gy in 1 fraction, Rectal balloon with air filling, Urethral catheter loaded with beacon transponders
- Where
- Portugal
- Volunteers
- 200 people
- Sponsor
- Fundacao Champalimaud